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Thromboxane A2 Induces Itch-Associated Responses
through TP Receptors in the Skin in Mice
Tsugunobu Andoh1,5, Yumi Nishikawa1,5, Tomomi Yamaguchi-Miyamoto1, Hiroshi Nojima2, Shu Narumiya3
and Yasushi Kuraishi1,4
Thromboxane A2 (TXA2), a metabolite of arachidonic acid produced by cyclooxygenase and thromboxane
synthase, is thought to participate in chronic dermatitis. This study investigated the involvement of TXA2 in
cutaneous itch. An intradermal injection of U-46619, a stable analogue of TXA2, elicited scratching, an itch-
associated response, in mice. Dose–response curve was bell shaped with a maximum effect at 10 nmol per site.
The action of U-46619 was inhibited by a coinjection of the TP antagonist ONO-3708 and was abolished by TP
receptor deficiency. TP receptor was mainly expressed in nerve fiber in the skin and keratinocytes.
Thromboxane synthase was also expressed in keratinocytes. U-46619 increased intracellular Ca2þ ion
concentration in primary cultures of dorsal root ganglion neurons and keratinocytes. The results suggest that
TXA2 synthesized by keratinocytes acts as an itch mediator. It may elicit itch through the activation of TP
receptors on primary afferents and keratinocytes; keratinocytes may produce itch mediators including TXA2.
Thus, thromboxane synthase inhibitor and TP receptor antagonists will be candidates for antipruritic medicines.
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INTRODUCTION
Itch is a distressing symptom associated with a variety of
peripheral and systemic disorders. This sensation provokes a
desire to scratch and makes cutaneous symptom worse. H1
histamine receptor antagonists are the drugs of first choice for
the treatment of itch, but many pruritic diseases (e.g., atopic
dermatitis) except acute urticaria respond poorly to the H1
receptor antagonists (Wahlgren, 1991). Thus, the precise
mechanisms and mediators of itch in most pruritic diseases
are unclear.
Glucocorticoids suppress itch of severe chronic skin
diseases (Felix and Shuster, 1975). Glucocorticoids inhibit
the phospholipase A2 (Piltch et al., 1989) and regulate the
expression of cyclooxygenase-2, but not cyclooxygenase-1
(Zhang et al., 1999). Therefore, arachidonic acid metabolites
may be involved in the induction and/or enhancement of
itch. In human subjects, prostaglandin E2 is a weak pruritogen
(Ha¨germark and Strandberg (1977)) and prolongs experimen-
tally induced itch (Fjellner and Ha¨germark 1979; Ha¨germark
and Strandberg (1977)). In addition, itching of patients with
polycythemia vera is suppressed by the cyclooxygenase
inhibitor aspirin (Fjellner and Ha¨germark, 1979). In animal
experiments, an intradermal injection of prostaglandin E2
alone does not elicit itch-associated response (Andoh and
Kuraishi, 1998).
Thromboxane A2 (TXA2) is produced by catalysis with
cyclooxygenase and thromboxane synthase, and is altered
spontaneously to inactive TXB2. TXA2 exerts its actions
through a G-protein-coupled receptor, termed prostanoid
receptor (TP) (Narumiya et al., 1999). TXA2 is produced by
the platelets and affects the cardiovascular system (FitzGerald
et al., 1987), including platelet aggregation (Svensson et al.,
1976). The serum concentration of TXB2 is increased in
patients with pruritic diseases (Marks et al., 1984; Mysliwiec
et al., 1985; Grekas et al., 1989; Veale et al., 1994). It was
also increased in the skin of NC mice, which had chronic
dermatitis and showed chronic itch-associated behavior
(Andoh and Kuraishi, unpublished observation). However, it
is unclear whether TXA2 is involved in cutaneous itch. In this
study, we investigated whether TXA2 and TP receptor would
be involved in cutaneous itch.
RESULTS
U-46619 elicits scratching through TP receptor
As TXA2 is very unstable, we used U-46619, a stable analoge
of TXA2. An intradermal injection of U-46619 (10 nmol per
site), but not vehicle (0.2% ethanol in saline), markedly
elicited scratching of the injected site by the hind paw in
Institute for Cancer Research (ICR) mice (Figure 1). The effect
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peaked during the second 10-minutes period and almost
completely subsided by 60 minute (Figure 1a). U-46619 at
intradermal doses of 1–100 nmol per site elicited scratching;
the dose–response curve was bell-shaped with a peak effect at
10 nmol per site (Figure 1b). U-46619 at a dose of 100 nmol/
site elicited abnormal behaviors such as writhing and
crouching in three out of eight mice tested. Intradermal
injections of histamine at doses of 9–900 nmol per site
elicited scratching in a dose-dependent manner (Figure 1b).
The number of scratching induced by U-46619 (10 nmol per
site) was 3.6 times more than that by histamine (900 nmol per
site). Intraplantar injections of U-46619 (4 and 10 nmol
per site) did not produce licking behavior, a pain-related
response (data not shown).
Scratching elicited by U-46619 at a dose of 10 nmol per
site was dose dependently suppressed by coinjection of the
TP receptor antagonist ONO-3708 at doses of 0.1–1 nmol per
site (Figure 2). An intradermal injection of U-46619 (10 nmol
per site) did not elicit scratching in TP/ mice, although it
elicited substantial scratching in wild-type (C57BL/6) mice
(Figure 3).
Distribution of thromboxane synthase and TP receptor in the
skin
Immunohistochemical staining showed that thromboxane
synthase was expressed only in the epidermal keratinocytes;
the distinct immunoreactivity was not observed in the dermis.
(Figure 4a). On the other hand, TP receptors were localized
mainly in the keratinocytes, and also in the nerve fibers
positive for protein gene product 9.5, a pan-neuronal marker,
especially in the epidermis (Figure 4b). Figure 4c shows
frequency distribution of TP receptor-immunoreactive neu-
rons in the dorsal root ganglia. When 1,133 cultured dorsal
root ganglion neurons were examined, 597 neurons (53%)
were to be found immunoreactive for TP receptors. Four
hundred and twenty-four (78%) out of 544 small-size neurons
(p15 mm in diameter), 160 (48%) out of 331 medium-sized
neurons (415 and p25 mm), and 13 (5%) out of 258 large-
sized neurons (X25 mm) were immunoreactive for TP
receptor. Seventy-one percent of 597 TP-immunoreactive
neurons were small in size.
U-46619 activates dorsal root ganglion neurons and
keratinocytes through TP receptor
In the above behavioral experiments, an intradermal injec-
tion of U-46619 (10 nmol/50ml¼ 200mM) elicited scratching,
which was inhibited by ONO-3708 (1 nmol/50ml¼20 mM).
Therefore, in this series of in vitro experiments, U-46619 and
ONO-3708 were administered at the final concentrations of
200 and 20 mM, respectively. Figure 5a shows a typical
example of the response of primary culture of mouse dorsal
root ganglion neuron to U-46619. It was markedly increased
by the concentration of intracellular Ca2þ ions, which was
significantly suppressed in the presence of ONO-3708
(Figure 5a and b). The effect peaked around 1 minute after
administration and almost subsided by 8 minutes (Figure 5a).
Similar results were also obtained from primary culture of
mouse epidermal keratinocytes. U-46619 markedly increased
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Figure 1. Scratching after intradermal injection of the TP receptor agonist
U-44619 in ICR mice. (a) Time course of scratching after vehicle (upper
panel, 0.2% ethanol in saline) and U-46619 (lower panel, 10 nmol per site)
injection. (b) Dose–response curves for the scratch-inducing effects of
U-46619 and histamine. ICR mice were given an intradermal injection of
U-46619, histamine, or vehicle (VH; J, 0.2% ethanol in saline; &, 2%
ethanol in saline; W, saline). Values represent the means7SEM for eight
animals. *Po0.05 when compared with VH for each agent (Dunnett’s
multiple comparisons).
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Figure 2. Suppressive effects of the TP receptor antagonist ONO-3708 on
U-46619-induced scratching in ICR mice. U-46619 (10 nmol per site) was
injected intradermally alone (CNT) or together with ONO-3708 into ICR
mice. Dashed line shows data obtained from mice injected intradermally with
vehicle (0.2% ethanol in saline). Values represent the means7SEM for eight
animals. *Po0.05 when compared with CNT (Dunnett’s multiple
comparisons).
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Figure 3. Deficiency in TP thromboxane A2 receptor abolishes scratching
induced by intradermal injection of U-46619 in mice. U-46619 (10 nmol per
site) was injected intradermally into wild-type (C57BL/6 strain) and TP
receptor-deficient mice (TP-R/). Values represent the means7SEM for eight
animals. *Po0.05 when compared with wild type (Student’s t-test).
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the concentration of intracellular Ca2þ ions, but not in the
presence of ONO-3708, in keratinocytes (Figure 5c and d).
The effect peaked around 1 minute after administration and
almost subsided by 8 minutes (Figure 5c).
Administration of vehicles for ONO-3708 and U-46619
did not affect the concentration of intracellular Ca2þ ions in
the neurons and keratinocytes (data not shown).
DISCUSSION
An intradermal injection of the TP receptor agonist U-46619
elicited scratching of the injection site in mice. U-46619-
elicited scratching was abolished by deficiency in TP
receptor and was inhibited by the TP receptor antagonist
ONO-3708. ONO-3708 inhibits the receptor binding of
U-46619 but not of leukotriene D4, TXB2, and prostaglandins
D2 and E1 (Narumiya et al. 1986; Nagai et al., 1991).
Therefore, it is suggested that the action of U-46619 on the
skin elicits itch-related response through the stimulation of TP
receptors. The effect of U-46619 peaked at a dose of 10 nmol
per site, which was 10–100 times lower than those of
substance P (Andoh et al., 1998), histamine (Andoh and
Kuraishi (2002)), serotonin (Yamaguchi et al., 1999), and
nociceptin (Andoh et al., 2004), and was about three times
more than that of leukotriene B4 (Andoh and Kuraishi, 1998).
The results, taken together, suggest that TXA2 is an itch
mediator in the skin. The number of scratching after a
100 nmol/site dose was less than that after a 10 nmol/site
dose. Systemic effects of U-46619 at the highest dose tested
might suppress itch-related behavior because it elicited
abnormal behaviors such as writhing and crouching.
TXA2 is synthesized from prostaglandin H2, a metabolite of
arachidonic acid, by thromboxane synthase (Needleman
et al., 1976). In the normal skin of the mice, thromboxane
synthase was exclusively expressed in the keratinocytes in the
epidermis, suggesting that the keratinocytes produce and
release TXA2 in the skin. In human subjects, oral aspirin was
reported not to affect itch of some pruritic diseases such as
chronic eczema, psoriasis, and biliary cirrhosis at an
analgesic dose (Daly and Shuster, 1986). On the other hand,
topical aspirin (twice daily at least for 2 weeks) was shown to
reduce pruritus of lichen simplex chronicus (Yosipovitch
et al. (2001)). There is no evidence that the inhibition of
cyclooxygenase is responsible for the anti-pruritic action of
aspirin, but it is interesting to investigate changes in the
concentration of TXA2 and the expression level of thrombox-
ane synthase in the epidermis of the affected skin. We do not
deny the possibility that TXA2 released from the platelets and/
or inflammatory cells including eosinophils (Kroegel et al.,
1994) is also involved in pruritus. For example, oral aspirin
(1.5 g daily for 1 week) alleviates the pruritus of polycythemia
vera (Fjellner and Ha¨germark, 1979). Proliferation of all
hematopoietic bone marrow cells including platelets abnor-
mally increased in this disorder, and the pruritus was
suggested to be mediated by prostaglandin E2 and serotonin
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Figure 4. Expression of thromboxane synthase and TP receptor in the mouse skin and dorsal root ganglion neurons. (a) Thromboxane synthase
immunoreactivity in the skin. It was observed in the epidermal keratinocytes. Bar¼20 mm. (b) TP receptor (TP-R) and PGP9.5 immunoreactivities in the skin.
TP-R (green) was observed in the epidermal keratinocytes. Scale bar¼ 20mm. (c) Frequency distribution of TP-R-positive neurons in the dorsal root ganglion.
Closed and open columns indicate TP-R-positive (n¼ 597) and negative neurons (n¼ 536), respectively.
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released from platelets. However, as platelets also synthesize
and release TXA2, it seems possible that TXA2 is involved in
the pruritus of polycythemia vera.
Mast cells constitutively express thromboxane synthase
transcripts, and the immunological stimulation of cultured
mast cells produces TXA2, the amount of which is much less
than those of other arachidonic acid metabolites prostaglan-
din D2 and leukotriene C4 (Mita et al., 1999). In this study,
thromboxane synthase immunoreactivity was not obvious in
mast cells in the normal skin. Thus, the results do not provide
support for the active involvement of mast cell-derived TXA2
in itching, but we do not deny the possibility of the
involvement in itch of dermatitis.
In the skin, the TP receptor was expressed in the epidermal
keratinocytes and primary afferent neurons, especially in the
nerve fibers and terminals in the epidermis. TP receptors were
mainly expressed in small-sized neurons in the dorsal root
ganglion. Small-sized neurons have chiefly unmyelinated C
fibers (Harper and Lowson, 1985: Lee et al., 1986), which
play an important role in itch signaling (Handwerker et al.
(1991); Schmeltz et al., 1997). U-46619 stimulated TP
receptors on primary cultures of the dorsal root ganglion
neurons to increase the concentration of intracellular Ca2þ
ions. Although TP receptor is a G protein-coupled receptor
(Hirata et al., 1991), the action of U-44619 is inhibited by
L-type calcium channel inhibitor nifedipine, suggesting that
U-46619 causes membrane depolarization (Arshad et al.,
2006). Thus, it is suggested that TXA2 produced by
keratinocytes acts on the keratinocytes as an autocrine factor
and also on primary afferents.
The increase of intracellular Ca2þ concentration induced
by U-44619 in the primary sensory neuron subsided by
8 minutes after the application. If TP receptors on the primary
afferents are primary site of pruritogenic action of U-44619,
scratching elicited by intradermal U-44619 is expected to
subside by 10 minutes. However, the scratching behavior
peaked after 10 minutes and lasted around 50 minutes. TP
receptors were also expressed on the keratinocytes, and
activation by U-44619 increased the concentration of
intracellular Ca2þ ions. Activation of keratinocytes by several
kinds of stimuli releases itch mediators, for example,
leukotriene B4, nociceptin, and TXA2 itself, and itch
enhancers, for example, oxide (Andoh et al., 2001, 2004;
Andoh and Kuraishi (2003)). The autocrine action of TXA2 on
the keratinocytes may increase and prolong the pruritogenic
action of U-44619.
Application of nucleus pulposus to the lumbar nerve root
causes hyperalgesia, which is relieved by an epidural
injection of a thromboxane synthase inhibitor in rats; the
effect is not obvious 30 minutes after injection and becomes
apparent after 3 and 7 days (Kawakami et al., 2001). Thus, it
is suggested that TXA2 produced in the inflamed tissue plays a
role in hyperalgesia. In this study, an intraplantar injection of
U-46619 at a pruritogenic dose did not elicit pain-related
response for at least 1 hour. Thus, it is suggested that TXA2 is a
cause of inflammatory hyperalgesia and a pruritogen but not
an algogen.
Based on our results, the suggested mechanisms of the
TXA2-induced itching are illustrated in Figure 6. Some
pruritogenic stimulation may activate the keratinocytes to
produce and release TXA2 in the epidermis. TXA2 directly
stimulates primary afferents, which conduct itch signal to the
central nervous system. The action of TXA2 on primary
afferents may also result in sensitization of primary afferents
to itch mediator(s) and the release of transmitter(s), for
example, substance P, in the epidermis. TXA2 and the
transmitter(s) released act on the keratinocytes, which release
several kinds of itch mediators and itch enhancers. At
present, pruritic skin diseases in which TXA2 is involved are
not known. But thromboxane synthase and TP receptor may
become new targets for the treatment of pruritic skin diseases.
MATERIALS AND METHODS
Animals
Male ICR mice (4–5 weeks old or neonatal; Shizuoka, Japan) were
used. In one series of experiments, TP receptor-deficient (TP/)
mice with a genetic background of C57BL/6 were used at 16 weeks
of age (Xiao et al., 2001). The mice except neonates were housed in
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Figure 5. U-46619-induced increase in the concentration of intracellular
Ca2þ ions in the cultured mouse dorsal root ganglion neurons and
keratinocytes. Typical examples of time-course of U-46619-induced changes
in the concentration of intracellular Ca2þ ions (fluorescence) in the dorsal
root ganglion neuron (a) and keratinocytes (c) Maximal change in the
U-46619-induced increase of intracellular Ca2þ ions in the dorsal root
ganglion neurons (b, n¼ 20) and keratinocytes (d, n¼ 33). Primary cultures
of mouse dorsal root ganglion neurons and keratinocytes were preloaded
with fluo-3. U-46619 was administered to the culture medium at the final
concentration of 200 mM. ONO-3708 (final concentration of 10 mM) and
vehicle (VH) were administered 5 minutes before U-46619. Values
represent the means7SEM. *Po0.05 when compared with VH.
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a room under controlled temperature (22711C), humidity
(55710%), and light (lights on from 0700 to 1900 hours). Food
and water were freely available. Procedures in the animal experi-
ments were approved by the Committee for Animal Experiments at
University of Toyama.
Materials
For in vivo experiments, 9,11-dideoxy-9a,11a-methanoepoxy prosta-
glandin F2a (U-46619; Cayman Chemical, Ann Arbor, MI) was
dissolved in physiological saline containing 0.2 (for 1 and 10 nmol
per site) or 2% ethanol (for 100 nmol per site). For in vitro
experiment, U-46619 was dissolved in DMSO and diluted with
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer. Histamine
(Wako Pure Chemical Ind., Osaka, Japan) was dissolved in
physiological saline. 7-[2a, 4a-(dimethylmethano)-6b-(2-cyclohex-
yl-2b-hydoxyacetamino)-1a-cyclohexyl]-5(Z)-heptanoic acid (ONO-
3708; Ono Phamaceutical Co. Ltd., Osaka, Japan) was dissolved in
saline or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer.
Capsaicin (Sigma, St Louis, MI) was dissolved in 0.2% ethanol.
Behavioral experiments
For intradermal injection, the hair was clipped over the rostral part of
the mouse back. The next day, U-46619 or histamine was injected
intradermally in a volume of 50 ml into the interscapular region. For
the observation of pain-related behavior, U-46619 was injected
subcutaneously into the plantar region of the hind paw in a volume
of 20 ml. Before behavior observation, the animals were placed
individually into an acrylic cage composed of four cells
(13 9 30 cm) for at least 1 hour for acclimation. Immediately
after intradermal or subcutaneous injection, the animals were put
back into the same cells and their behaviors were videotaped using
an 8-mm video camera for 1 hour with personnel kept out of the
observation room. Playing back of the video served for the
determination of scratching of the rostral back or licking of the hind
paw (Kuraishi et al., 1995).
Measurement of intracellular Ca2þ concentration
The bilateral dorsal root ganglia at the T1–L6 levels were removed
from the mice and cells were dissociated with 0.25% collagenase
(Wako Pure Chemical). The cells were cultured in DMEM (Invitro-
gen, Carlsbad, CA) containing 10% heat-inactivated fetal bovine
serum in the presence of 2mM cytosine arabinoside (Sigma, St Louis,
MO), which kills glial cells, for at least 7 days. To prepare
keratinocytes, skin was removed from neonatal mice and was
treated with 0.05% collagenase A (Roche Diagnostics GmbH,
Mannheim, Germany) dissolved in mouse keratinocyte growth
medium (1.076% MCDB 153s (Sigma, St Louis, MI), 0.67% 4-(2-
hydroxyethyl)-1- piperazineethanesulfonic acid, 0.12% NaHCO3,
0.01% penicillin G, and 0.006% kanamycin) at 41C overnight. The
keratinocytes were cultured in mouse keratinocyte growth medium
containing 5mg/ml insulin, 0.5 mg/ml hydrocortisone, 14.1mg/ml
phosphorylethanolamine, 0.01 mg/ml epidermal growth factor,
10 mg/ml transferrin, and 0.1 mg/ml bovine pituitary extract. The
primary cultures of dorsal root ganglion neurons and keratinocytes
were washed with the medium Opti-MEMs (Invitrogen), incubated
with 10mM fluo-3/AM (Dojindo, Kumamoto, Japan) in Opti-MEM
containing 0.05% poloxamer (Calbiochem, Dermstadt, Germany),
and then washed with Opti-MEM. Intracellular Ca2þ concentration
was measured using a laser-scanning microscope system (Radiance
2100; Bio-Rad, Hercules, CA) at 515–545 nm emission with
excitation at 488 nm. As all of the dorsal root ganglion neurons
did not express TP receptors, they were stimulated twice by U-46619
and data were obtained from neurons that responded to the second
stimulation. The same procedures were applied to keratinocytes,
although almost all keratinocytes responded to U-46619.
Immunocytochemistry
The dorsal root ganglia at the T1–L6 levels and the skin were
removed from young mice. The dorsal root ganglion cells were
prepared and cultured as mentioned above. The tissues and cultured
neurons were fixed with 4% paraformaldehyde at 41C for 1 hour and
then were immersed in 30% sucrose solution overnight at 41C. The
tissues were frozen and sectioned at 30 mm with a cryostat. After
being washed three times with 0.1 M phosphate buffer, the sections
were treated with the first antibody at a dilution of 1/500 at 41C
overnight. Antibodies used were goat anti-TP receptor antibody
(Santa Cruz Biotechnology Inc., Santa Cruz, CA), rabbit anti-
thromboxane synthase antibody (Cayman Chemical) and rabbit
anti-human protein gene product 9.5 antibody (Nordic Immunology,
Tilburg, Netherlands). After being washed, the preparations treated
with anti-TP receptor and anti-thromboxane antibodies were
incubated with Alexa Fluor 488-conjugated anti-goat IgG antibody,
and those treated with anti-human PGP9.5 antibody were incubated
with Alexa Fluor 594-conjugated anti-rabbit IgG antibody for 1 hour
at room temperature. Fluorescence signals were observed using a
confocal laser scanning microscope (Bio-Rad).
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Figure 6. Schema of the mechanisms of thromboxane A2-mediated itch.
Thromboxane synthase is expressed in the epidermal keratinocytes (KC) and
TP receptor (TP-R) is expressed in the KC and primary sensory neurons. KCs
may produce and release thromboxane A2 (TXA2), which may act on primary
afferents to produce itch signals. TXA2 may also act on KCs to release itch
mediators including TXA2 itself.
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Data processing
All data are presented as means7SEM. Statistical significance was
analyzed using Dunnett’s multiple comparisons or Student’s t-test;
*Po0.05 was considered significant.
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